N. Schraps, Anne Menz, F. Viehweger, Ş. Büyücek, D. Dum, R. Schlichter, A. Hinsch, Christoph Fraune, C. Bernreuther, M. Kluth, C. Hube-Magg, K. Möller, V. Reiswich, A. Luebke, P. Lebok, S. Weidemann, G. Sauter, M. Lennartz, F. Jacobsen, T. Clauditz, A. Marx, R. Simon, Stefan Steurer, B. Mercanoglu, N. Melling, T. Hackert, Eike C. Burandt, N. Gorbokon, S. Minner, T. Krech, F. Lutz, Morton Freytag
2026.3.1Cancer Medicine
tlooto Summary
The prevalence and clinical relevance of CA19‐9 expression in human cancer is evaluated to evaluate the prevalence and clinical relevance of the glycoprotein in human cancer.
Abstract
Carbohydrate antigen 19–9 (CA19‐9) is a cell surface glycoprotein widely used as a diagnostic and prognostic serum marker for monitoring pancreatic cancer. The aim of this study was to evaluate the prevalence and clinical relevance of CA19‐9 expression in human cancer.
Citation format
SCHRAPS, N., et al. Pattern and clinical significance of CA19‐9 expression in human cancer: A tissue microarray study on 14,966 tumors. Cancer Medicine, 2026, 15(3): e71710.